Form 4: IDEAYA Biosciences Executive Acquires 75,000 Stock Options

Andres Ruiz Briseno, SVP, Head of Finance and Investor Relations at IDEAYA Biosciences, acquired 75,000 stock options on February 27, 2025.

Summary

• On February 27, 2025, Andres Ruiz Briseno, SVP, Head of Finance and Investor Relations at IDEAYA Biosciences, acquired 75,000 stock options.
• The exercise price of these options is $20.24.
• The options vest over four years, starting January 1, 2025, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
• The options expire on February 26, 2035.
• Following the transaction, Ruiz Briseno directly owns 75,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option acquisition. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding more than 10% of the company's shares) buy or sell the company's securities. This filing indicates a transaction by an executive at IDEAYA Biosciences.

Stakeholder Impact

• The acquisition of stock options by an executive could be seen as a positive sign by shareholders, indicating confidence in the company's future performance.
• Employees may view this as a positive incentive for management.

Key Dates